SciSparc’s subsidiary NeuroThera Labs Initiates Phase IIb Clinical Trial Site At Hannover Medical School In Germany For SCI-110, Proprietary Cannabinoid-Based Treatment Candidate For Tourette Syndrome In Adults

SciSparc Adds Prof. Carmel Domshlak To Newly Established Scientific Advisory Board For AI And Cybersecurity, Effective September 1

The addition of leading AI researcher further strengthens SciSparc’s scientific and technical foundation as the Company advances its strategic focus on the Agentic AI marketTEL AVIV, Israel, Aug. 26, 2026 (GLOBE

SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating Disorders

SciSparc shares are trading higher. The company announced its majority-owned subsidiary, NeuroThera Labs, has completed two tranches of non-brokered private placements, raising aggregate gross proceeds of C$5.4 million.

16.86 -1.64 [-8.86%]

SciSparc Invests C$2.7 Million In NeuroThera Financing, Raising Stake To 44.6% Valued At ~C$30 Million

SciSparc Invests C$2.7 million and holds approximately 44.6% of NeuroThera’s issued and outstanding common shares following the financingTEL AVIV, Israel, Aug. 18, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC)

SciSparc's NeuroThera Labs Initiates Phase IIb Clinical Study To Evaluate SCI-110 Drug Candidate To Treat Tourette Syndrome

SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel

SciSparc's NeuroThera Labs Subsidiary Completes Internal Validation Of Quantum Sampling Workflow Developed Platform For Clinical Trials Data Analysis